| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 26 | 2024 | 1771 | 2.510 |
Why?
|
| Breast Neoplasms | 52 | 2021 | 3053 | 2.390 |
Why?
|
| Randomized Controlled Trials as Topic | 26 | 2025 | 887 | 2.300 |
Why?
|
| Research Design | 12 | 2025 | 600 | 2.250 |
Why?
|
| Antineoplastic Agents, Hormonal | 18 | 2024 | 149 | 1.980 |
Why?
|
| Neoplasm Recurrence, Local | 23 | 2024 | 1398 | 1.650 |
Why?
|
| Androgen Antagonists | 11 | 2024 | 139 | 1.580 |
Why?
|
| Tamoxifen | 20 | 2014 | 168 | 1.540 |
Why?
|
| Proportional Hazards Models | 21 | 2024 | 871 | 1.260 |
Why?
|
| Neoplasms | 17 | 2025 | 3117 | 1.230 |
Why?
|
| Brain Neoplasms | 8 | 2024 | 800 | 1.220 |
Why?
|
| Data Interpretation, Statistical | 9 | 2024 | 306 | 1.200 |
Why?
|
| Glioblastoma | 5 | 2024 | 274 | 1.140 |
Why?
|
| Clinical Trials as Topic | 14 | 2025 | 1150 | 1.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2016 | 171 | 0.960 |
Why?
|
| Statistics as Topic | 2 | 2021 | 234 | 0.940 |
Why?
|
| Survival Analysis | 21 | 2024 | 1511 | 0.820 |
Why?
|
| Disease-Free Survival | 29 | 2024 | 1181 | 0.770 |
Why?
|
| Models, Statistical | 6 | 2017 | 578 | 0.750 |
Why?
|
| Obesity | 6 | 2021 | 1016 | 0.750 |
Why?
|
| Humans | 127 | 2025 | 92337 | 0.740 |
Why?
|
| Prostate-Specific Antigen | 9 | 2024 | 341 | 0.740 |
Why?
|
| Receptors, Estrogen | 17 | 2012 | 401 | 0.720 |
Why?
|
| Biomarkers, Tumor | 11 | 2019 | 1576 | 0.720 |
Why?
|
| Antineoplastic Agents | 13 | 2021 | 2368 | 0.690 |
Why?
|
| Middle Aged | 74 | 2024 | 27030 | 0.620 |
Why?
|
| Aged | 59 | 2024 | 19943 | 0.610 |
Why?
|
| Biomarkers | 3 | 2021 | 1850 | 0.600 |
Why?
|
| Medical Futility | 1 | 2016 | 32 | 0.520 |
Why?
|
| Prognosis | 25 | 2024 | 3872 | 0.510 |
Why?
|
| Chemotherapy, Adjuvant | 14 | 2011 | 485 | 0.500 |
Why?
|
| Risk Assessment | 14 | 2024 | 2369 | 0.490 |
Why?
|
| Male | 51 | 2024 | 43925 | 0.490 |
Why?
|
| Salvage Therapy | 3 | 2024 | 234 | 0.490 |
Why?
|
| Female | 74 | 2024 | 47893 | 0.490 |
Why?
|
| Colonic Neoplasms | 6 | 2016 | 583 | 0.470 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2015 | 153 | 0.460 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 268 | 0.440 |
Why?
|
| Radiation Oncology | 2 | 2016 | 122 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2014 | 2556 | 0.430 |
Why?
|
| Odds Ratio | 11 | 2020 | 694 | 0.420 |
Why?
|
| Treatment Outcome | 24 | 2024 | 8740 | 0.420 |
Why?
|
| Disease Progression | 10 | 2020 | 1503 | 0.420 |
Why?
|
| Neoplasm Staging | 19 | 2018 | 2035 | 0.420 |
Why?
|
| Prostatectomy | 5 | 2024 | 479 | 0.410 |
Why?
|
| Likelihood Functions | 3 | 2014 | 252 | 0.390 |
Why?
|
| Body Mass Index | 5 | 2013 | 800 | 0.390 |
Why?
|
| Clinical Trials Data Monitoring Committees | 2 | 2016 | 5 | 0.380 |
Why?
|
| Medical Oncology | 3 | 2024 | 393 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2018 | 866 | 0.380 |
Why?
|
| Lymph Nodes | 4 | 2012 | 552 | 0.360 |
Why?
|
| Survival Rate | 17 | 2017 | 1927 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1939 | 0.350 |
Why?
|
| Time Factors | 15 | 2024 | 5430 | 0.340 |
Why?
|
| Follow-Up Studies | 17 | 2024 | 3775 | 0.340 |
Why?
|
| Biometry | 3 | 2011 | 68 | 0.330 |
Why?
|
| Neoplasms, Second Primary | 5 | 2006 | 245 | 0.330 |
Why?
|
| Aged, 80 and over | 20 | 2020 | 6916 | 0.320 |
Why?
|
| Patient Compliance | 1 | 2011 | 236 | 0.320 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 498 | 0.320 |
Why?
|
| Cognition Disorders | 1 | 2011 | 240 | 0.320 |
Why?
|
| Estrogen Antagonists | 5 | 2004 | 47 | 0.310 |
Why?
|
| Lymphatic Metastasis | 11 | 2012 | 498 | 0.310 |
Why?
|
| Adult | 34 | 2020 | 27532 | 0.300 |
Why?
|
| Risk Factors | 16 | 2024 | 5704 | 0.300 |
Why?
|
| Health Status Disparities | 2 | 2011 | 201 | 0.300 |
Why?
|
| Multicenter Studies as Topic | 6 | 2012 | 172 | 0.290 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 259 | 0.290 |
Why?
|
| United States | 19 | 2025 | 7348 | 0.280 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2018 | 127 | 0.270 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 6 | 2011 | 118 | 0.270 |
Why?
|
| Neoplasm Grading | 8 | 2024 | 390 | 0.260 |
Why?
|
| Pleural Neoplasms | 3 | 2013 | 201 | 0.260 |
Why?
|
| Health Services Accessibility | 4 | 2021 | 451 | 0.250 |
Why?
|
| Mesothelioma | 4 | 2013 | 327 | 0.250 |
Why?
|
| Cause of Death | 3 | 2019 | 270 | 0.250 |
Why?
|
| Mastectomy, Segmental | 8 | 2011 | 101 | 0.240 |
Why?
|
| Genes, BRCA1 | 4 | 2008 | 192 | 0.240 |
Why?
|
| Drug Administration Schedule | 5 | 2018 | 868 | 0.230 |
Why?
|
| Quality of Life | 5 | 2022 | 1744 | 0.230 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2003 | 10 | 0.230 |
Why?
|
| Endpoint Determination | 3 | 2020 | 57 | 0.230 |
Why?
|
| Incidence | 6 | 2022 | 1661 | 0.210 |
Why?
|
| Tosyl Compounds | 3 | 2021 | 13 | 0.210 |
Why?
|
| Radiotherapy | 6 | 2017 | 324 | 0.210 |
Why?
|
| Combined Modality Therapy | 12 | 2017 | 1733 | 0.210 |
Why?
|
| Anilides | 3 | 2021 | 45 | 0.210 |
Why?
|
| Mass Screening | 4 | 2019 | 675 | 0.200 |
Why?
|
| Nitriles | 3 | 2021 | 158 | 0.200 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 23 | 0.200 |
Why?
|
| Dacarbazine | 4 | 2017 | 101 | 0.200 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2002 | 160 | 0.190 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 1071 | 0.190 |
Why?
|
| Rectal Neoplasms | 1 | 2003 | 133 | 0.180 |
Why?
|
| Immunotherapy | 2 | 2024 | 725 | 0.180 |
Why?
|
| Social Class | 2 | 2016 | 138 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2017 | 134 | 0.170 |
Why?
|
| Radiotherapy Dosage | 3 | 2019 | 475 | 0.170 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 2394 | 0.170 |
Why?
|
| Electronic Mail | 1 | 2020 | 17 | 0.170 |
Why?
|
| Pneumonia | 1 | 2022 | 189 | 0.170 |
Why?
|
| Coronavirus | 1 | 2020 | 18 | 0.170 |
Why?
|
| Kallikreins | 1 | 2020 | 46 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2012 | 168 | 0.170 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2024 | 281 | 0.170 |
Why?
|
| Hypersensitivity | 1 | 2022 | 163 | 0.170 |
Why?
|
| Treatment Failure | 4 | 2017 | 289 | 0.170 |
Why?
|
| Patient Readmission | 1 | 2024 | 393 | 0.160 |
Why?
|
| Confidence Intervals | 2 | 2014 | 219 | 0.160 |
Why?
|
| Double-Blind Method | 9 | 2020 | 1756 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 4 | 2011 | 1076 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2004 | 404 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2018 | 1091 | 0.160 |
Why?
|
| Breast | 3 | 2013 | 289 | 0.160 |
Why?
|
| Educational Status | 3 | 2020 | 197 | 0.160 |
Why?
|
| Risk | 5 | 2019 | 661 | 0.160 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2019 | 35 | 0.150 |
Why?
|
| Radiosurgery | 1 | 2022 | 297 | 0.150 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 58 | 0.150 |
Why?
|
| Cisplatin | 2 | 2018 | 602 | 0.150 |
Why?
|
| Tobacco Smoking | 1 | 2018 | 30 | 0.150 |
Why?
|
| Papillomavirus Infections | 2 | 2018 | 274 | 0.150 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 47 | 0.150 |
Why?
|
| Cetuximab | 1 | 2018 | 114 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 105 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2012 | 429 | 0.150 |
Why?
|
| Computer Simulation | 4 | 2014 | 1111 | 0.150 |
Why?
|
| Patient Participation | 1 | 2020 | 228 | 0.150 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 444 | 0.140 |
Why?
|
| Prospective Studies | 7 | 2022 | 4468 | 0.140 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 154 | 0.140 |
Why?
|
| Life Expectancy | 2 | 2009 | 89 | 0.140 |
Why?
|
| Receptors, Progesterone | 5 | 2012 | 179 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 743 | 0.140 |
Why?
|
| Socioeconomic Factors | 4 | 2010 | 611 | 0.130 |
Why?
|
| Genes, BRCA2 | 2 | 2008 | 161 | 0.130 |
Why?
|
| SEER Program | 3 | 2019 | 229 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2020 | 364 | 0.130 |
Why?
|
| Internal-External Control | 1 | 2016 | 45 | 0.130 |
Why?
|
| Mammography | 4 | 2013 | 471 | 0.120 |
Why?
|
| Coronary Disease | 1 | 1997 | 262 | 0.120 |
Why?
|
| Religion | 1 | 2016 | 88 | 0.120 |
Why?
|
| Nomograms | 2 | 2012 | 33 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 328 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 313 | 0.120 |
Why?
|
| Probability | 1 | 2016 | 357 | 0.120 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1119 | 0.120 |
Why?
|
| Epidemiologic Research Design | 1 | 2014 | 22 | 0.120 |
Why?
|
| Health Literacy | 1 | 2016 | 73 | 0.120 |
Why?
|
| Registries | 3 | 2024 | 902 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 812 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2014 | 595 | 0.110 |
Why?
|
| Cohort Studies | 5 | 2022 | 2978 | 0.110 |
Why?
|
| ErbB Receptors | 3 | 2012 | 498 | 0.110 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 45 | 0.110 |
Why?
|
| Retrospective Studies | 7 | 2024 | 9703 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 296 | 0.100 |
Why?
|
| alpha-Tocopherol | 1 | 2013 | 9 | 0.100 |
Why?
|
| Selenomethionine | 1 | 2013 | 11 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 226 | 0.100 |
Why?
|
| Cyclophosphamide | 4 | 2012 | 304 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1138 | 0.100 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 469 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 73 | 0.100 |
Why?
|
| Age Factors | 5 | 2020 | 1905 | 0.100 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2019 | 181 | 0.100 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2012 | 98 | 0.100 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 15 | 0.100 |
Why?
|
| Drug Design | 1 | 2012 | 130 | 0.100 |
Why?
|
| Arsenic Poisoning | 1 | 2013 | 103 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 2394 | 0.100 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2012 | 25 | 0.100 |
Why?
|
| Body Weight | 3 | 2013 | 456 | 0.090 |
Why?
|
| Antioxidants | 1 | 2013 | 224 | 0.090 |
Why?
|
| Bias | 3 | 2025 | 137 | 0.090 |
Why?
|
| DNA Methylation | 4 | 2015 | 677 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1763 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 542 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 977 | 0.090 |
Why?
|
| Stroke | 1 | 2000 | 1038 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2012 | 296 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 3 | 2008 | 569 | 0.080 |
Why?
|
| Comorbidity | 2 | 2024 | 987 | 0.080 |
Why?
|
| Chemoradiotherapy | 3 | 2018 | 318 | 0.080 |
Why?
|
| Decision Making | 3 | 2016 | 680 | 0.080 |
Why?
|
| Death Certificates | 1 | 2009 | 11 | 0.080 |
Why?
|
| Genes, erbB-2 | 1 | 2009 | 25 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1191 | 0.080 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2010 | 62 | 0.080 |
Why?
|
| Pneumonectomy | 1 | 2012 | 215 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 400 | 0.080 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 523 | 0.080 |
Why?
|
| Quinazolines | 1 | 2010 | 214 | 0.080 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 358 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2009 | 214 | 0.070 |
Why?
|
| Time | 1 | 2008 | 79 | 0.070 |
Why?
|
| Fanconi Anemia Complementation Group F Protein | 1 | 2007 | 6 | 0.070 |
Why?
|
| Fallopian Tubes | 1 | 2008 | 46 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2008 | 86 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 606 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2012 | 473 | 0.070 |
Why?
|
| Prevalence | 2 | 2024 | 1294 | 0.070 |
Why?
|
| Mutation | 3 | 2008 | 4204 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2012 | 901 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 2006 | 1045 | 0.070 |
Why?
|
| Parent-Child Relations | 1 | 2007 | 81 | 0.070 |
Why?
|
| Disclosure | 1 | 2007 | 109 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2007 | 178 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 151 | 0.060 |
Why?
|
| Survival | 1 | 2006 | 21 | 0.060 |
Why?
|
| Flutamide | 2 | 2017 | 3 | 0.060 |
Why?
|
| Goserelin | 2 | 2017 | 5 | 0.060 |
Why?
|
| Vulnerable Populations | 1 | 2007 | 84 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2007 | 159 | 0.060 |
Why?
|
| Aneuploidy | 1 | 2005 | 58 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 108 | 0.060 |
Why?
|
| Proton Therapy | 2 | 2016 | 36 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 186 | 0.060 |
Why?
|
| North America | 1 | 2005 | 188 | 0.060 |
Why?
|
| Control Groups | 1 | 2025 | 16 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2014 | 389 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 42 | 0.060 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2004 | 34 | 0.060 |
Why?
|
| Technology, Radiologic | 2 | 2016 | 104 | 0.060 |
Why?
|
| Logistic Models | 2 | 2020 | 1239 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 305 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2003 | 32 | 0.050 |
Why?
|
| Body Composition | 1 | 2003 | 72 | 0.050 |
Why?
|
| Travel | 1 | 2003 | 72 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 130 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2004 | 139 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2004 | 121 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2011 | 1684 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2004 | 266 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2004 | 180 | 0.050 |
Why?
|
| Lomustine | 2 | 2012 | 26 | 0.050 |
Why?
|
| Chicago | 2 | 2024 | 1466 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 270 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 694 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2012 | 72 | 0.050 |
Why?
|
| Young Adult | 2 | 2012 | 6624 | 0.050 |
Why?
|
| Bevacizumab | 2 | 2014 | 270 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2004 | 453 | 0.050 |
Why?
|
| Consensus | 1 | 2004 | 376 | 0.050 |
Why?
|
| Hematuria | 1 | 2022 | 50 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2004 | 497 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2004 | 443 | 0.050 |
Why?
|
| Carcinoma in Situ | 2 | 1999 | 53 | 0.040 |
Why?
|
| Computational Biology | 1 | 2024 | 566 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1095 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2025 | 425 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 159 | 0.040 |
Why?
|
| Selection Bias | 1 | 2020 | 36 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 709 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 955 | 0.040 |
Why?
|
| Monte Carlo Method | 2 | 2014 | 188 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 996 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2020 | 69 | 0.040 |
Why?
|
| Prostate | 1 | 2023 | 413 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2020 | 359 | 0.040 |
Why?
|
| Patient Selection | 1 | 2003 | 689 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 34 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2729 | 0.040 |
Why?
|
| Contrast Media | 1 | 2004 | 1076 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 2 | 2012 | 260 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2019 | 85 | 0.040 |
Why?
|
| Mastectomy | 3 | 2012 | 257 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 443 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2012 | 3508 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2013 | 2680 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 968 | 0.040 |
Why?
|
| China | 1 | 2019 | 248 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1247 | 0.040 |
Why?
|
| Fluorouracil | 3 | 2011 | 549 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 184 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 41 | 0.040 |
Why?
|
| Re-Irradiation | 1 | 2017 | 15 | 0.040 |
Why?
|
| Informed Consent | 1 | 2020 | 278 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 269 | 0.030 |
Why?
|
| Gynecomastia | 1 | 2017 | 8 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 74 | 0.030 |
Why?
|
| Canada | 2 | 2011 | 205 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 154 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 74 | 0.030 |
Why?
|
| Leucovorin | 2 | 2011 | 222 | 0.030 |
Why?
|
| Income | 1 | 2016 | 87 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 315 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 806 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 29 | 0.030 |
Why?
|
| Leuprolide | 1 | 2014 | 35 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2016 | 158 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 56 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 229 | 0.030 |
Why?
|
| Information Dissemination | 1 | 1995 | 119 | 0.030 |
Why?
|
| Markov Chains | 1 | 2014 | 131 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 154 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 222 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1997 | 402 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 1998 | 657 | 0.030 |
Why?
|
| Lung Volume Measurements | 1 | 2013 | 21 | 0.030 |
Why?
|
| Cytostatic Agents | 1 | 2012 | 4 | 0.030 |
Why?
|
| Cytotoxins | 1 | 2012 | 16 | 0.030 |
Why?
|
| Postmenopause | 1 | 2013 | 102 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 1995 | 308 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 293 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2012 | 76 | 0.020 |
Why?
|
| Glutamates | 1 | 2012 | 89 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2012 | 41 | 0.020 |
Why?
|
| Sample Size | 1 | 2012 | 126 | 0.020 |
Why?
|
| Credentialing | 1 | 2012 | 14 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2012 | 80 | 0.020 |
Why?
|
| Bangladesh | 1 | 2013 | 332 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2012 | 36 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 3509 | 0.020 |
Why?
|
| Taxoids | 1 | 2012 | 126 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 179 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2005 | 490 | 0.020 |
Why?
|
| Levamisole | 1 | 2011 | 6 | 0.020 |
Why?
|
| Guanine | 1 | 2012 | 207 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 299 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2012 | 98 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2012 | 212 | 0.020 |
Why?
|
| Vincristine | 1 | 2011 | 109 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 2009 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2012 | 175 | 0.020 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2011 | 21 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2005 | 236 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 128 | 0.020 |
Why?
|
| DNA Damage | 1 | 2012 | 381 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 366 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 291 | 0.020 |
Why?
|
| Glioma | 1 | 2012 | 303 | 0.020 |
Why?
|
| Senegal | 1 | 2009 | 4 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 304 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 446 | 0.020 |
Why?
|
| beta Catenin | 1 | 2011 | 266 | 0.020 |
Why?
|
| Nigeria | 1 | 2009 | 160 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2005 | 2037 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2005 | 2669 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 242 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 448 | 0.020 |
Why?
|
| Genetic Carrier Screening | 1 | 2008 | 59 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2794 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 97 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 1310 | 0.020 |
Why?
|
| CpG Islands | 1 | 2007 | 163 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1807 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 619 | 0.020 |
Why?
|
| Methotrexate | 2 | 1997 | 245 | 0.020 |
Why?
|
| Pedigree | 1 | 2008 | 966 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 379 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 50 | 0.020 |
Why?
|
| Adolescent | 2 | 2009 | 9504 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 211 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 891 | 0.020 |
Why?
|
| Models, Econometric | 1 | 2005 | 13 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 2448 | 0.020 |
Why?
|
| Value of Life | 1 | 2005 | 22 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2005 | 79 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2005 | 211 | 0.010 |
Why?
|
| Minority Groups | 1 | 2006 | 150 | 0.010 |
Why?
|
| Azacitidine | 1 | 2005 | 148 | 0.010 |
Why?
|
| ROC Curve | 1 | 2007 | 785 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2004 | 153 | 0.010 |
Why?
|
| BRCA1 Protein | 1 | 2005 | 207 | 0.010 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2004 | 19 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 550 | 0.010 |
Why?
|
| Interleukin-18 | 1 | 2004 | 26 | 0.010 |
Why?
|
| Lymphopenia | 1 | 2004 | 32 | 0.010 |
Why?
|
| Receptors, Interferon | 1 | 2004 | 32 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 900 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2004 | 54 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1902 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 476 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2004 | 111 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2004 | 180 | 0.010 |
Why?
|
| Pyrroles | 1 | 2004 | 171 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2004 | 255 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2003 | 197 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 289 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 358 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2006 | 390 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 307 | 0.010 |
Why?
|
| Indoles | 1 | 2004 | 306 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 701 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 277 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 901 | 0.010 |
Why?
|
| Cognition | 1 | 2007 | 603 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2004 | 828 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 1312 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2007 | 1774 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 1180 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 787 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 474 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2001 | 82 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 353 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 1141 | 0.010 |
Why?
|
| Melanoma | 1 | 2004 | 482 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 28003 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 1228 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 754 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 1863 | 0.010 |
Why?
|
| Necrosis | 1 | 1999 | 209 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 2087 | 0.010 |
Why?
|
| Carcinoma, Lobular | 1 | 1999 | 81 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 188 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 767 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 2498 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 1277 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 3360 | 0.010 |
Why?
|
| Child | 1 | 2007 | 7334 | 0.010 |
Why?
|
| Federal Government | 1 | 1995 | 29 | 0.010 |
Why?
|
| Government Regulation | 1 | 1995 | 50 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 1996 | 212 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 12110 | 0.010 |
Why?
|